3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid has been researched along with Facial Pain in 1 studies
3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid: structure given in first source; NMDA receptor antagonist
Facial Pain: Pain in the facial region including orofacial pain and craniofacial pain. Associated conditions include local inflammatory and neoplastic disorders and neuralgic syndromes involving the trigeminal, facial, and glossopharyngeal nerves. Conditions which feature recurrent or persistent facial pain as the primary manifestation of disease are referred to as FACIAL PAIN SYNDROMES.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yang, GY | 1 |
| Woo, YW | 1 |
| Park, MK | 1 |
| Bae, YC | 1 |
| Ahn, DK | 1 |
| Bonfa, E | 1 |
1 other study available for 3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid and Facial Pain
| Article | Year |
|---|---|
Intracisternal administration of NR2 antagonists attenuates facial formalin-induced nociceptive behavior in rats.
Topics: Animals; Behavior, Animal; Cisterna Magna; Disease Models, Animal; Excitatory Amino Acid Antagonists | 2010 |